4.6 Article

Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing

期刊

出版社

BMC
DOI: 10.1186/s40478-019-0873-5

关键词

Multiple system atrophy; Parkinson's disease; Alpha-synuclein; SNCA; Somatic mutation; Single cell sequencing; Mosaicism

资金

  1. Michael J Fox Foundation for Parkinson's Research
  2. National Institute for Health Research University College London Hospitals Biomedical Research Centre
  3. Edmond J. Safra Foundation
  4. Francis Crick Institute from Cancer Research UK [FC001202]
  5. UK Medical Research Council [FC001202]
  6. Wellcome Trust [FC001202, WT093205MA, WT104033/Z/14/Z]
  7. Department of Health's NIHR Biomedical Research Centre's funding scheme
  8. Multiple System Atrophy Trust
  9. Multiple System Atrophy Coalition
  10. Fund Sophia
  11. MSA Trust
  12. Medical Research Council (MRC UK) [MR/J004758/1, G0802760, G1001253]
  13. Association of British Neurologists' Academic Clinical Training Research Fellowship
  14. Reta Lila Weston Institute for Neurological Studies
  15. Medical Research Council UK
  16. Parkinson's UK, a charity registered in England and Wales [258197]
  17. Parkinson's UK, a charity registered in Scotland [SC037554]
  18. MRC [MR/J004758/1, G0802760, G1001253] Funding Source: UKRI

向作者/读者索取更多资源

Synucleinopathies are mostly sporadic neurodegenerative disorders of partly unexplained aetiology, and include Parkinson's disease (PD) and multiple system atrophy (MSA). We have further investigated our recent finding of somatic SNCA (alpha-synuclein) copy number variants (CNVs, specifically gains) in synucleinopathies, using Fluorescent in-situ Hybridisation for SNCA, and single-cell whole genome sequencing for the first time in a synucleinopathy. In the cingulate cortex, mosaicism levels for SNCA gains were higher in MSA and PD than controls in neurons (> 2% in both diseases), and for MSA also in non-neurons. In MSA substantia nigra (SN), we noted SNCA gains in > 3% of dopaminergic (DA) neurons (identified by neuromelanin) and neuromelanin-negative cells, including olig2-positive oligodendroglia. Cells with CNVs were more likely to have alpha-synuclein inclusions, in a pattern corresponding to cell categories mostly relevant to the disease: DA neurons in Lewy-body cases, and other cells in the striatonigral degeneration-dominant MSA variant (MSA-SND). Higher mosaicism levels in SN neuromelanin-negative cells may correlate with younger onset in typical MSA-SND, and in cingulate neurons with younger death in PD. Larger sample sizes will, however, be required to confirm these putative findings. We obtained genome-wide somatic CNV profiles from 169 cells from the substantia nigra of two MSA cases, and pons and putamen of one. These showed somatic CNVs in similar to 30% of cells, with clonality and origins in segmental duplications for some. CNVs had distinct profiles based on cell type, with neurons having a mix of gains and losses, and other cells having almost exclusively gains, although control data sets will be required to determine possible disease relevance. We propose that somatic SNCA CNVs may contribute to the aetiology and pathogenesis of synucleinopathies, and that genome-wide somatic CNVs in MSA brain merit further study.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据